DongKook Life Science동국생명과학

DongKook Life Science's shares have fallen sharply over the past year, while its trailing profit has recovered from 2024 levels.

The company, a Korean maker and distributor of imaging contrast agents, reported trailing twelve-month revenue of about ₩117.7B to H1 2026 with operating income of about ₩10.2B and net income of about ₩4.9B. The stock closed at ₩2,280 on 2026-10-26, down 39.6% over one year and about 19% over one month, and sits near the lower part of its 52-week range. The data includes a DCF-based base value of ₩3,853, but the model's inputs and method details are limited.

What stands out

• Trailing revenue is about ₩117.7B, down from ₩130.3B in 2025 and ₩131.8B in 2024, so top-line growth has been negative.
• Operating margin is 8.7% on a trailing basis, versus 10% for full-year 2025, while full-year 2025 net income of ₩8.7B was well above 2024's ₩2.2B.
• Valuation metrics are modest: P/E about 14.8, P/B about 0.5, and no dividend yield; cash is about ₩5.2B and borrowings are not reported.
• Recent filings include the annual report, quarterly and half-year reports, and a shareholders' meeting notice dated 2026-10-26.
• News reports say the company is pursuing a name change to 'DK Luonics' (also reported as DK Luonix) and expanding its new drug and CMO business, targeting global markets.

What to watch

• The shareholders' meeting and the record date notice, including any proposed name change and business expansion details.
• Next quarterly results, to see whether revenue decline and margin pressure continue in the new drug and CMO push.
• Foreign ownership rose from 2.5% to 3.4% over 60 days, while foreign investors were net sellers over the last 20 days; the data does not explain the reasons.